Deseret Mutual Benefit Administrators Has $175,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Deseret Mutual Benefit Administrators lifted its stake in Zoetis Inc. (NYSE:ZTS) by 17.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,007 shares of the company’s stock after acquiring an additional 151 shares during the quarter. Deseret Mutual Benefit Administrators’ holdings in Zoetis were worth $175,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Private Wealth Management Group LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at approximately $33,000. Webster Bank N. A. lifted its stake in Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after acquiring an additional 82 shares during the last quarter. Gladius Capital Management LP bought a new position in shares of Zoetis in the 4th quarter valued at about $40,000. Neo Ivy Capital Management acquired a new position in shares of Zoetis during the 4th quarter worth about $40,000. Finally, EdgeRock Capital LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $45,000. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the subject of a number of research analyst reports. Stifel Nicolaus reiterated a “buy” rating and set a $200.00 price target on shares of Zoetis in a report on Tuesday, August 27th. Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. HSBC reduced their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Finally, BTIG Research increased their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus price target of $217.11.

Zoetis Stock Performance

Shares of Zoetis stock traded down $0.50 during trading on Thursday, reaching $186.83. The company’s stock had a trading volume of 34,485 shares, compared to its average volume of 2,652,960. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The firm has a market cap of $85.25 billion, a PE ratio of 36.09, a P/E/G ratio of 2.81 and a beta of 0.88. The business’s 50-day moving average price is $180.70 and its 200-day moving average price is $174.48. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same quarter in the prior year, the business posted $1.41 EPS. The business’s revenue was up 8.3% compared to the same quarter last year. Equities analysts forecast that Zoetis Inc. will post 5.84 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.